Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Total Enrollment
2604 participants
Study Classification
OBSERVATIONAL
Study Start Date
2010-05-31
Study Completion Date
2011-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The AVIS Study is a retrospective multicenter international study that aims to answer a series of questions on the use and performance of adrenal venous catheterization (AVS) for the diagnosis of primary hyperaldosteronism subtype. A questionnaire will be circulated among the centres that are internationally recognized and have published in the field of AVS and have agreed to participate in the study.
The first aim of the AVIS study is to collect summary data on how AVS is being performed throughout the world to answer the following questions:
* How many AVS studies haw been performed yearly from 2005 to 2010 at each center?
* How many adrenal vein ruptures occurred during the AVS at each center?Has the rate of adrenal vein rupture been steady or has it changed over the 5 years?
* How many centers use bilaterally simultaneous and how many use sequential AVS catheterization?
* How many radiologists perform AVS at each center?
* How many centers use a cosyntropin stimulation during AVS?
* What is the percentage of PA patients in whom AVS is performed?
* How many centres calculate the selectivity index? What is the minimum cutoff used?
* How many centers calculate the lateralization index? What is the minimum cutoff used?
* Are the AVS studies that are not bilaterally selective used for diagnosis?
* How many centers calculate the controlateral suppression index and what is the minimum cutoff used?
* What is the cost of AVS for the National Health System or Insurance and for patients? The second aim of the study is to calculate the rate of AVS studies that are selective and show lateralization of aldosterone excess at each center by applying predefined set of criteria for defining selectivity and lateralization. Data on the final diagnosis of the PA subtype will be gathered and used as reference to assess the performance of AVS using receiver operating characteristic curves analysis and the Youden index to determine the optimal cutoffs. A worksheet will need to be completed providing information on the following: Demography; Date of AVS;Baseline blood pressure (BP) values and serum K+;Dynamic test during the AVS if any; plasma aldosterone and cortisol concentration in the infra-adrenal inferior vena cava and in the right and left adrenal vein; diagnosis of PA subtype; treatment (adrenalectomy or pharmacological therapy); post-treatment BP and serum K+ values; concordance/discordance between imaging (CT or RM) and AVS.
The first aim of the AVIS study is to collect summary data on how AVS is being performed throughout the world to answer the following questions:
* How many AVS studies haw been performed yearly from 2005 to 2010 at each center?
* How many adrenal vein ruptures occurred during the AVS at each center?Has the rate of adrenal vein rupture been steady or has it changed over the 5 years?
* How many centers use bilaterally simultaneous and how many use sequential AVS catheterization?
* How many radiologists perform AVS at each center?
* How many centers use a cosyntropin stimulation during AVS?
* What is the percentage of PA patients in whom AVS is performed?
* How many centres calculate the selectivity index? What is the minimum cutoff used?
* How many centers calculate the lateralization index? What is the minimum cutoff used?
* Are the AVS studies that are not bilaterally selective used for diagnosis?
* How many centers calculate the controlateral suppression index and what is the minimum cutoff used?
* What is the cost of AVS for the National Health System or Insurance and for patients? The second aim of the study is to calculate the rate of AVS studies that are selective and show lateralization of aldosterone excess at each center by applying predefined set of criteria for defining selectivity and lateralization. Data on the final diagnosis of the PA subtype will be gathered and used as reference to assess the performance of AVS using receiver operating characteristic curves analysis and the Youden index to determine the optimal cutoffs. A worksheet will need to be completed providing information on the following: Demography; Date of AVS;Baseline blood pressure (BP) values and serum K+;Dynamic test during the AVS if any; plasma aldosterone and cortisol concentration in the infra-adrenal inferior vena cava and in the right and left adrenal vein; diagnosis of PA subtype; treatment (adrenalectomy or pharmacological therapy); post-treatment BP and serum K+ values; concordance/discordance between imaging (CT or RM) and AVS.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
CHina Adrenal Venous saMPling InvestigatiON
NCT07252284
Hyperaldosteronism
Adrenal Venous Sampling
Adrenalectomy
RECRUITING
Effect of Water Intake and Water Restriction on Total Kidney Volume in Autosomal Dominant Polycystic Kidney Disease
NCT02776241
ADPKD
COMPLETED
NA
ADVOS® Versus CVVHD in Metabolic or Mixed Acidosis
NCT05842369
Metabolic Acidosis
UNKNOWN
NA
Homburg Renal Evaluation Study on the Clinical Utility of Early AKI Diagnosis
NCT06180551
Acute Kidney Injury
RECRUITING
Active Surveillance of the Small Renal Mass
NCT02204800
Small Renal Mass, Kidney Cancer
COMPLETED
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Background. AVS is recommended by the current Endocrine Society Guideline as the gold standard for the identification of the surgically curable subtype of primary aldosteronism (PA).(Funder 2008) However, consensus on the way AVS should be performed and on the interpretation of its results still lacks, as recently pointed out. (Stewart 2010, Auchus 2010) In particular, some centers use the bilateral simultaneous technique, while others perform the sequential catheterization. Moreover, some centers perform AVS during or after using ACTH stimulation, albeit with different doses, and others do not use any stimulation.(Seccia 2009) In addition, some are utilizing the absolute values of plasma cortisol and aldosterone to determinate the lateralization (Nishikawa 2007), whereas others are relying on calculation of the selectivity index to determine the collection of adrenal vein blood, followed by calculation of the and the lateralization index only if bilaterally selective samples were obtained.(Rossi 2008) Moreover, large differences in the cutoffs for establishing selectivity and lateralization exist, which have not been clarified by recent studies that rather added further complexity to this field.(Mulatero 2010) If a consistent degree of success rate can be achieved by having only one or two radiologists performing AVS at each centre, or if more radiologists can become proficient in performing the procedure and consistently achieving adequate results, also remains to be clarified. Finally, some centers perform AVS in all patients who are plausible candidates to adrenalectomy, while other submit to AVS only a small proportion of the patients (Young WJ personal communication).
Thus, it remains unclear which is the proportion of patients with PA who are offered AVS at the different centers, and how many of those who are submitted to AVS ultimately undergo adrenalectomy.
In an era of shrinking budget the issue of cost the issue of costs of the procedure also remains a relevant one when assessing the cost-effectiveness of the diagnostic work-up of PA. A preliminary survey suggests that there are huge variations across different countries in the charges for AVS to both the patients and/or the health care and insurance system.
It is likely that one of the reasons for the lack of consensus on AVS could depend on the facts that: i) no single centre as gathered a number of AVS studies large enough to warrant solid conclusions; ii) there has been no systematic survey of the AVS data that have been generated around the world in this field
Aims of the study. Based on this background, the aims of the AVIS study are those described above.
Study design. To the first aim a questionnaire will be circulated among the centers that are internationally recognized and have published in the field of AVS and have agreed to participate in the study.
The data will be collected and handled at the maximum level of confidentiality under the requirement of the Declaration of Helsinki.
Study selection criteria. Eligible centers will be identified among those that have published in the English literature on AVS or PA (reported variously as observational cohort studies, or clinical trials): Studies will be identified through computer-assisted literature searches of databases, scanning of reference lists, hand-searching of relevant journals, correspondence with authors of relevant reports and consultation with experts in the field.
The inclusion criteria will be the consent of the leading investigator to participate in the data collection.
The only exclusion criteria will be the refusal to participate in the study. The number of adhering and non-adhering centers will be recorded and mentioned in the publications.
Data collection. Data will be collected in an anonymous way on many characteristics at baseline and at subsequent surveys during follow-up. Information on categorical variables, will be systematically re-coded to ensure comparability among studies. For each individual patient, data were sought on the following outcomes: blood pressure and antihypertensive medications at follow-up post-adrenalectomy and on dates of occurrence of cardiovascular events, including non-fatal CHD; non fatal stroke; specific cause mortality (or at least fatal CDH and fatal stroke) and other cardiovascular outcomes. Being a retrospective study, precise details of the diagnostic criteria used for the definition of incident cases will be sought from each centre (as were data on the completeness of follow-up).
Data obtained from each participating study will be checked for internal consistency and any queries that might arrive will clarified with the P.I. of each centre, before harmonization to a standard format.
The content of the data will be unchanged by this process, and computer-generated detailed summary tabulations based will be reviewed and confirmed by collaborators.
Data will be stored securely and anonymously at the coordinating centre.
Statistical analysis will be performed by use of summary statistics after appropriate transformation of the variables that show a skewed distribution as PAC and PCC by means of the SPSS for Mac (vers 18.0), GaphPad and the MedCalc softwares.
Scientific Committee. The leading investigator of each centre contributing at least 50 AVS studies will be invited to participate in the scientific committee of the AVIS study and will have full access to the locked database.
Expected results. Upon completion of the first phase of the study the investigators expect to be able to gather information on the way AVS is being performed around the world and therefore to prepare a first manuscript reporting on the number of AVS per centre, the rate of adrenal vein ruptures during the procedure, the rate of use of simultaneous/sequential AVS catheterization, the number of radiologists that perform AVS and their success rate in the procedure, the rate of use of stimulation test during the perform of AVS, the percentage of PA patients to whom AVS is offered at each center, the rate of calculation of the selectivity index, the lateralization index and the contralateral suppression index and their cutoff limits, the use of AVS studies that are not bilaterally selective for diagnosis and the costs of AVS for the National Health System or Insurance and for the patients.
Upon completion of the database with the individual data the investigators expect to be able to gather \> 2000 AVS studies, in a single database. After harmonization of the data, identification of the outliers and of the underlying reasons (by interaction with the leading investigator at each center), the database will be locked. The investigators will then undertake the statistical analysis, which will entail the following variables:
* Demography (sex, age, race);
* Baseline blood pressure (BP) and heart rate (HR) values;
* Serum K+ before AVS;
* Dynamic test during the AVS if any;
* Plasma aldosterone (PAC) and cortisol concentration (PCC) in the infraadrenal inferior vena cava (IVC) and in the right (RAV) and left (LAV) adrenal vein;
* Final diagnosis (bilateral adrenocortical hyperplasia (BAH), unilateral adrenocortical hyperplasia (UAH), aldosterone-producing adenoma (APA), bilateral APA;
* Treatment (adrenalectomy or pharmacological therapy);
* Post-treatment blood pressure (BP) and heart rate (HR) values;
* Post-treatment sK+ ;
* Diagnosis concordance/discordance between imaging (CT or RM) and AVS. Data on the demography, biochemical and hemodynamic features of the patients selected for AVS in the different continents will be obtained and information on the rate of successful catheterization will be generated. The concordance rate of imaging and AVS results will also be determined and the clinical usefulness of the AVS for establishing the indication to adrenalectomy will be ascertained in the largest database available ever.
Thus, it remains unclear which is the proportion of patients with PA who are offered AVS at the different centers, and how many of those who are submitted to AVS ultimately undergo adrenalectomy.
In an era of shrinking budget the issue of cost the issue of costs of the procedure also remains a relevant one when assessing the cost-effectiveness of the diagnostic work-up of PA. A preliminary survey suggests that there are huge variations across different countries in the charges for AVS to both the patients and/or the health care and insurance system.
It is likely that one of the reasons for the lack of consensus on AVS could depend on the facts that: i) no single centre as gathered a number of AVS studies large enough to warrant solid conclusions; ii) there has been no systematic survey of the AVS data that have been generated around the world in this field
Aims of the study. Based on this background, the aims of the AVIS study are those described above.
Study design. To the first aim a questionnaire will be circulated among the centers that are internationally recognized and have published in the field of AVS and have agreed to participate in the study.
The data will be collected and handled at the maximum level of confidentiality under the requirement of the Declaration of Helsinki.
Study selection criteria. Eligible centers will be identified among those that have published in the English literature on AVS or PA (reported variously as observational cohort studies, or clinical trials): Studies will be identified through computer-assisted literature searches of databases, scanning of reference lists, hand-searching of relevant journals, correspondence with authors of relevant reports and consultation with experts in the field.
The inclusion criteria will be the consent of the leading investigator to participate in the data collection.
The only exclusion criteria will be the refusal to participate in the study. The number of adhering and non-adhering centers will be recorded and mentioned in the publications.
Data collection. Data will be collected in an anonymous way on many characteristics at baseline and at subsequent surveys during follow-up. Information on categorical variables, will be systematically re-coded to ensure comparability among studies. For each individual patient, data were sought on the following outcomes: blood pressure and antihypertensive medications at follow-up post-adrenalectomy and on dates of occurrence of cardiovascular events, including non-fatal CHD; non fatal stroke; specific cause mortality (or at least fatal CDH and fatal stroke) and other cardiovascular outcomes. Being a retrospective study, precise details of the diagnostic criteria used for the definition of incident cases will be sought from each centre (as were data on the completeness of follow-up).
Data obtained from each participating study will be checked for internal consistency and any queries that might arrive will clarified with the P.I. of each centre, before harmonization to a standard format.
The content of the data will be unchanged by this process, and computer-generated detailed summary tabulations based will be reviewed and confirmed by collaborators.
Data will be stored securely and anonymously at the coordinating centre.
Statistical analysis will be performed by use of summary statistics after appropriate transformation of the variables that show a skewed distribution as PAC and PCC by means of the SPSS for Mac (vers 18.0), GaphPad and the MedCalc softwares.
Scientific Committee. The leading investigator of each centre contributing at least 50 AVS studies will be invited to participate in the scientific committee of the AVIS study and will have full access to the locked database.
Expected results. Upon completion of the first phase of the study the investigators expect to be able to gather information on the way AVS is being performed around the world and therefore to prepare a first manuscript reporting on the number of AVS per centre, the rate of adrenal vein ruptures during the procedure, the rate of use of simultaneous/sequential AVS catheterization, the number of radiologists that perform AVS and their success rate in the procedure, the rate of use of stimulation test during the perform of AVS, the percentage of PA patients to whom AVS is offered at each center, the rate of calculation of the selectivity index, the lateralization index and the contralateral suppression index and their cutoff limits, the use of AVS studies that are not bilaterally selective for diagnosis and the costs of AVS for the National Health System or Insurance and for the patients.
Upon completion of the database with the individual data the investigators expect to be able to gather \> 2000 AVS studies, in a single database. After harmonization of the data, identification of the outliers and of the underlying reasons (by interaction with the leading investigator at each center), the database will be locked. The investigators will then undertake the statistical analysis, which will entail the following variables:
* Demography (sex, age, race);
* Baseline blood pressure (BP) and heart rate (HR) values;
* Serum K+ before AVS;
* Dynamic test during the AVS if any;
* Plasma aldosterone (PAC) and cortisol concentration (PCC) in the infraadrenal inferior vena cava (IVC) and in the right (RAV) and left (LAV) adrenal vein;
* Final diagnosis (bilateral adrenocortical hyperplasia (BAH), unilateral adrenocortical hyperplasia (UAH), aldosterone-producing adenoma (APA), bilateral APA;
* Treatment (adrenalectomy or pharmacological therapy);
* Post-treatment blood pressure (BP) and heart rate (HR) values;
* Post-treatment sK+ ;
* Diagnosis concordance/discordance between imaging (CT or RM) and AVS. Data on the demography, biochemical and hemodynamic features of the patients selected for AVS in the different continents will be obtained and information on the rate of successful catheterization will be generated. The concordance rate of imaging and AVS results will also be determined and the clinical usefulness of the AVS for establishing the indication to adrenalectomy will be ascertained in the largest database available ever.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Hyperaldosteronism
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Observational Model Type
COHORT
Study Time Perspective
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Adrenal Venous Sampling (AVS)
Patients with Primary Aldosteronism (PA) undergoing AVS to discriminate PA forms with unilateral from bilateral excess aldosterone production.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* consent of the leading investigator to participate to the data collection
Exclusion Criteria
* refusal of the leading investigator to participate to the AVIS Study
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital Padova
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Gian Paolo Rossi, MD, FAHA, FACC
MD, FAHA, FACC
Responsibility Role
PRINCIPAL_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
GianPaolo Rossi, MD, FACC
Role: STUDY_DIRECTOR
Dept Clinical and Experimental Medicine (DMCS), University Hospital of Padova, Italy
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hospital of The University of Pennsylvania, Philadelphia
Philadelphia, Pennsylvania, United States
Site Status
UT Southwestern Medical Center
Dallas, Texas, United States
Site Status
Medical College of Wisconsin
Menomonee Falls, Wisconsin, United States
Site Status
Endocrine Hypertension Research Centre, University of Queensland School of Medicine, Greenslopes Hospital
Brisbane, , Australia
Site Status
Foothills Medical Centre, University of Calgary
Calgary, Alberta, Canada
Site Status
Centre Hospitalier de l'Université de Montreal (CHUM)
Montreal, Quebec, Canada
Site Status
General Faculty Hospital, Prague
Prague, , Czechia
Site Status
University of Paris, Hopital Européen Georges Pompidou
Paris, , France
Site Status
Christian J Strasburger
Berlin, , Germany
Site Status
Heinrich Heine Universität Düsseldorf
Düsseldorf, , Germany
Site Status
Medizinische Klinik Innenstadt
Munich, , Germany
Site Status
University Hospital Wuerzburg
Würzburg, , Germany
Site Status
Dept Clinical and Experimental Medicine (DMCS), University Hospital of Padova, Italy
Padua, , Italy
Site Status
Medicina 2, Dipartimento di Medicina Interna e Specialità Mediche, Azienda Ospedaliera Santa Maria Nuova
Reggio Emilia, , Italy
Site Status
National Hospital Organizatio, Kyoto Medical Center
Kyoto, , Japan
Site Status
Tohoku University Hospital
Sendai, , Japan
Site Status
Institute of Clinical Endocrinology, Tokyo Women's Medical University
Tokyo, , Japan
Site Status
Yokohama Rosai Hospital
Yokohama, , Japan
Site Status
Radboud University Nijmegen Medical Center
Nijmegen, , Netherlands
Site Status
National Taiwan University Hospital
Taipei, , Taiwan
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
Australia
Canada
Czechia
France
Germany
Italy
Japan
Netherlands
Taiwan
References
Explore related publications, articles, or registry entries linked to this study.
Funder J, Carey R, Fardella C, Gomez-Sanchez C, Mantero F, Stowasser M, Young W, Montori VM. Withdrawn: Case detection, diagnosis, and treatment of patients with primary aldosteronism: an Endocrine Society clinical practice guideline. Eur J Endocrinol. 2009 Sep 30. doi: 10.1530/EJE-09-0870. Online ahead of print.
Reference Type
BACKGROUND
Stewart PM, Allolio B. Adrenal vein sampling for Primary Aldosteronism: time for a reality check. Clin Endocrinol (Oxf). 2010 Feb;72(2):146-8. doi: 10.1111/j.1365-2265.2009.03714.x. Epub 2009 Sep 21. No abstract available.
Reference Type
BACKGROUND
Seccia TM, Miotto D, De Toni R, Pitter G, Mantero F, Pessina AC, Rossi GP. Adrenocorticotropic hormone stimulation during adrenal vein sampling for identifying surgically curable subtypes of primary aldosteronism: comparison of 3 different protocols. Hypertension. 2009 May;53(5):761-6. doi: 10.1161/HYPERTENSIONAHA.108.128553. Epub 2009 Apr 6.
Reference Type
BACKGROUND
Rossi GP, Pitter G, Bernante P, Motta R, Feltrin G, Miotto D. Adrenal vein sampling for primary aldosteronism: the assessment of selectivity and lateralization of aldosterone excess baseline and after adrenocorticotropic hormone (ACTH) stimulation. J Hypertens. 2008 May;26(5):989-97. doi: 10.1097/HJH.0b013e3282f9e66a.
Reference Type
BACKGROUND
Mulatero P, Bertello C, Sukor N, Gordon R, Rossato D, Daunt N, Leggett D, Mengozzi G, Veglio F, Stowasser M. Impact of different diagnostic criteria during adrenal vein sampling on reproducibility of subtype diagnosis in patients with primary aldosteronism. Hypertension. 2010 Mar;55(3):667-73. doi: 10.1161/HYPERTENSIONAHA.109.146613. Epub 2010 Feb 1.
Reference Type
BACKGROUND
Auchus RJ, Wians FH Jr, Anderson ME, Dolmatch BL, Trimmer CK, Josephs SC, Chan D, Toomay S, Nwariaku FE. What we still do not know about adrenal vein sampling for primary aldosteronism. Horm Metab Res. 2010 Jun;42(6):411-5. doi: 10.1055/s-0030-1252060. Epub 2010 Apr 21.
Reference Type
BACKGROUND
Nishikawa T, Saito J, Omura M. Adrenal venous sampling is absolutely requisite for definitively diagnosing primary aldosteronism as well as for detecting laterality of the adrenal lesion. Hypertens Res. 2007 Nov;30(11):1009-10. doi: 10.1291/hypres.30.1009. No abstract available.
Reference Type
BACKGROUND
Pintus G, Seccia TM, Amar L, Azizi M, Riester A, Reincke M, Widimsky J, Naruse M, Kocjan T, Negro A, Kline G, Tanabe A, Satoh F, Rump LC, Vonend O, Fuller PJ, Yang J, Chee NYN, Magill SB, Shafigullina Z, Quinkler M, Oliveras A, Lee BC, Chang CC, Wu VC, Kratka Z, Battistel M, Bagordo D, Caroccia B, Ceolotto G, Rossitto G, Rossi GP. Subtype Identification of Surgically Curable Primary Aldosteronism During Treatment With Mineralocorticoid Receptor Blockade. Hypertension. 2024 Jun;81(6):1391-1399. doi: 10.1161/HYPERTENSIONAHA.124.22721. Epub 2024 Mar 25.
Reference Type
DERIVED
Rossi GP, Bagordo D, Amar L, Azizi M, Riester A, Reincke M, Degenhart C, Widimsky J, Naruse M, Deinum J, Kocjan T, Negro A, Rossi E, Kline G, Tanabe A, Satoh F, Rump LC, Vonend O, Willenberg HS, Fuller PJ, Yang J, Chee NYN, Magill SB, Shafigullina Z, Quinkler M, Oliveras A, Lee BC, Chang CC, Wu VC, Kratka Z, Battistel M, Rossitto G, Seccia TM. Unilaterally Selective Adrenal Vein Sampling for Identification of Surgically Curable Primary Aldosteronism. Hypertension. 2023 Oct;80(10):2003-2013. doi: 10.1161/HYPERTENSIONAHA.123.21247. Epub 2023 Jun 15.
Reference Type
DERIVED
Rossi GP, Crimi F, Rossitto G, Amar L, Azizi M, Riester A, Reincke M, Degenhart C, Widimsky J, Naruse M, Deinum J, Kool LS, Kocjan T, Negro A, Rossi E, Kline G, Tanabe A, Satoh F, Rump LC, Vonend O, Willenberg HS, Fuller PJ, Yang J, Chee NYN, Magill SB, Shafigullina Z, Quinkler M, Oliveras A, Wu VC, Kratka Z, Barbiero G, Battistel M, Seccia TM. Feasibility of Imaging-Guided Adrenalectomy in Young Patients With Primary Aldosteronism. Hypertension. 2022 Jan;79(1):187-195. doi: 10.1161/HYPERTENSIONAHA.121.18284. Epub 2021 Nov 17.
Reference Type
DERIVED
Rossi GP, Crimi F, Rossitto G, Amar L, Azizi M, Riester A, Reincke M, Degenhart C, Widimsky J, Naruse M, Deinum J, Schultze Kool L, Kocjan T, Negro A, Rossi E, Kline G, Tanabe A, Satoh F, Christian Rump L, Vonend O, Willenberg HS, Fuller PJ, Yang J, Chee NYN, Magill SB, Shafigullina Z, Quinkler M, Oliveras A, Cent Wu V, Kratka Z, Barbiero G, Seccia TM, Battistel M. Identification of Surgically Curable Primary Aldosteronism by Imaging in a Large, Multiethnic International Study. J Clin Endocrinol Metab. 2021 Oct 21;106(11):e4340-e4349. doi: 10.1210/clinem/dgab482.
Reference Type
DERIVED
Rossitto G, Amar L, Azizi M, Riester A, Reincke M, Degenhart C, Widimsky J, Naruse M, Deinum J, Schultzekool L, Kocjan T, Negro A, Rossi E, Kline G, Tanabe A, Satoh F, Rump LC, Vonend O, Willenberg HS, Fuller P, Yang J, Nian Chee NY, Magill SB, Shafigullina Z, Quinkler M, Oliveras A, Chang CC, Wu VC, Somloova Z, Maiolino G, Barbiero G, Battistel M, Lenzini L, Quaia E, Pessina AC, Rossi GP. Subtyping of Primary Aldosteronism in the AVIS-2 Study: Assessment of Selectivity and Lateralization. J Clin Endocrinol Metab. 2020 Jun 1;105(6):dgz017. doi: 10.1210/clinem/dgz017.
Reference Type
DERIVED
Rossi GP, Rossitto G, Amar L, Azizi M, Riester A, Reincke M, Degenhart C, Widimsky J Jr, Naruse M, Deinum J, Schultze Kool L, Kocjan T, Negro A, Rossi E, Kline G, Tanabe A, Satoh F, Christian Rump L, Vonend O, Willenberg HS, Fuller PJ, Yang J, Chee NYN, Magill SB, Shafigullina Z, Quinkler M, Oliveras A, Dun Wu K, Wu VC, Kratka Z, Barbiero G, Battistel M, Chang CC, Vanderriele PE, Pessina AC. Clinical Outcomes of 1625 Patients With Primary Aldosteronism Subtyped With Adrenal Vein Sampling. Hypertension. 2019 Oct;74(4):800-808. doi: 10.1161/HYPERTENSIONAHA.119.13463. Epub 2019 Sep 3.
Reference Type
DERIVED
Rossi GP, Barisa M, Allolio B, Auchus RJ, Amar L, Cohen D, Degenhart C, Deinum J, Fischer E, Gordon R, Kickuth R, Kline G, Lacroix A, Magill S, Miotto D, Naruse M, Nishikawa T, Omura M, Pimenta E, Plouin PF, Quinkler M, Reincke M, Rossi E, Rump LC, Satoh F, Schultze Kool L, Seccia TM, Stowasser M, Tanabe A, Trerotola S, Vonend O, Widimsky J Jr, Wu KD, Wu VC, Pessina AC. The Adrenal Vein Sampling International Study (AVIS) for identifying the major subtypes of primary aldosteronism. J Clin Endocrinol Metab. 2012 May;97(5):1606-14. doi: 10.1210/jc.2011-2830. Epub 2012 Mar 7.
Reference Type
DERIVED
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GPR-AVIS
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Risk Stratification in End Stage Renal Disease (ESRD) - ISAR Study
NCT01152892
UNKNOWN
Evaluation of Novel Biomarkers From Acutely Ill Patients at Risk for Acute Kidney Injury
NCT01209169
COMPLETED
Drugmonitoring of Antiinfective Drugs in Patients Receiving Continous Veno-venous Hemodiafiltration (ABx-CVVHDF)
NCT02242721
WITHDRAWN
A Sample Collection Study to Validate the Astute Medical NephroCheck Test in Critically Ill Subjects at Risk for Acute Kidney Injury
NCT01573962
COMPLETED
Volume 3D_US Kidney
NCT03841149
COMPLETED
Inferior Vena cavaCollapsibility Index in Patients With Acute Kidney Injury
NCT02165072
COMPLETED
Personalized Versus Standard Hydration for Prevention of CI-AKI: a Randomized Trial With Bioimpedance Analysis
NCT02225431
COMPLETED
PHASE4
Observational Study in Patients With Autosomal Dominant Polycystic Kidney Disease
NCT01430494
COMPLETED
The German ADPKD Tolvaptan Treatment Registry
NCT02497521
RECRUITING
Intravenous vs. Oral Hydration to Reduce the Risk of Post-Contrast Acute Kidney Injury After Intravenous Contrast-Enhanced Computed Tomography in Patients With Severe Chronic Kidney Disease
NCT05283512
RECRUITING
NA
Advanced Ultrasound Applications for Predicting AVF Outcomes
NCT04141358
UNKNOWN
Acute Kidney Injury and Acute Kidney Disease in COVID-19
NCT04353583
COMPLETED
Protocol Active Surveillance Small Renal Masses (SRMs)
NCT03804320
RECRUITING
NA
Non-invasive Assessment to Predict Tolerance to Fluid Removal on Intermittent Kidney Replacement Therapy
NCT05270759
COMPLETED
REVERSE-AKI Randomized Controlled Pilot Trial
NCT03251131
COMPLETED
PHASE2
Diuresis, Functional Bladder Capacity and LUTS in CKD and ESRD Patients.
NCT04622215
COMPLETED
NA
Trial for the Early Identification of Acute Kidney Injury
NCT04200950
WITHDRAWN
PHASE2
Objective Markers and New Indicators in AI Disease (OMNI-AID Study)
NCT03615859
UNKNOWN
Observational Study of Pediatric Acute Kidney Injury, Risk Factors and Outcomes
NCT01987921
COMPLETED
Risk of Acute Kidney Injury in Patients Undergoing Cytoreductive Surgery and Hyperthermic Intra-peritoneal Chemotherapy
NCT04941625
UNKNOWN
Three-dimensional Virtual Imaging to Improve the Accuracy of Standard CT-based Nephrometric Scores: a Prospective Multicentric Observational Study
NCT05729763
COMPLETED
Differences in Urine NGAL Levels in Patients Undergoing RIRS With or Without Ureteral Access Sheath
NCT02485002
COMPLETED
NA
Intermittent Versus Continuous Renal Replacement Therapy for Acute Renal Failure
NCT00322933
TERMINATED
Carotid Doppler and IVC Measurements for Volume Guided Management in Acute Kidney Injury Patients
NCT05938049
NOT_YET_RECRUITING
The Predictive Performance of Renal Ultrasound on Changes in Renal Clearance
NCT04198168
TERMINATED